Onasemnogene Abeparvovcec Infusion and Zinbryta
Determining the interaction of Onasemnogene Abeparvovcec Infusion and Zinbryta and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration of daclizumab with other agents known to induce hepatotoxicity may increase the risk of liver injury. Serious drug-related hepatic injury, including liver failure and autoimmune hepatitis, has been reported across controlled and open-label studies in 1.7% of daclizumab-treated patients and may occur at any time during treatment and up to 5 months after treatment cessation. Fatal cases have occurred. In addition, cases of hepatic injury have occurred in patients taking daclizumab concomitantly with other hepatotoxic drugs; however, the contributory role of these other medicines has not been established. MANAGEMENT: Caution is advised if daclizumab is used with other potentially hepatotoxic agents, including non-prescription products and herbal supplements. Patients treated with daclizumab should have serum transaminase levels and total bilirubin measured prior to initiation of treatment and monthly during treatment in accordance with the manufacturer's recommendations, and the dosing adjusted or interrupted as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. References Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Zinbryta (daclizumab)." AbbVie US LLC, North Chicago, IL.
Professional:MONITOR: Coadministration of daclizumab with other agents known to induce hepatotoxicity may increase the risk of liver injury. Serious drug-related hepatic injury, including liver failure and autoimmune hepatitis, has been reported across controlled and open-label studies in 1.7% of daclizumab-treated patients and may occur at any time during treatment and up to 5 months after treatment cessation. Fatal cases have occurred. In addition, cases of hepatic injury have occurred in patients taking daclizumab concomitantly with other hepatotoxic drugs; however, the contributory role of these other medicines has not been established.
MANAGEMENT: Caution is advised if daclizumab is used with other potentially hepatotoxic agents, including non-prescription products and herbal supplements. Patients treated with daclizumab should have serum transaminase levels and total bilirubin measured prior to initiation of treatment and monthly during treatment in accordance with the manufacturer's recommendations, and the dosing adjusted or interrupted as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Zinbryta (daclizumab)." AbbVie US LLC, North Chicago, IL.
Generic Name: onasemnogene abeparvovec
Brand name: Zolgensma, Zolgensma
Synonyms: Onasemnogene abeparvovec (Zolgensma), Onasemnogene Abeparvovec
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Onasemnogene Abeparvovcec Infusion-Zinc
- Onasemnogene Abeparvovcec Infusion-Zinc acetate
- Onasemnogene Abeparvovcec Infusion-Zinc Chloride
- Onasemnogene Abeparvovcec Infusion-Zinc gluconate
- Onasemnogene Abeparvovcec Infusion-Zinc Gluconate Capsules and Tablets
- Onasemnogene Abeparvovcec Infusion-Zinc Gluconate Extended-Release Tablets
- Zinbryta-Onasemnogene Abeparvovec
- Zinbryta-Onasemnogene abeparvovec Zolgensma
- Zinbryta-Oncaspar
- Zinbryta-Oncovin
- Zinbryta-Ondansetron
- Zinbryta-Ondansetron and Dextrose